Company Overview - Iradimed is a specialized medical device company focused on MRI-compatible solutions, addressing critical needs in hospital imaging environments [6] - The company generates revenue through direct sales and distribution of proprietary medical equipment and consumables to healthcare facilities [9] - Revenue for the trailing twelve months (TTM) is approximately $80.5 million, with a net income of about $21.2 million [4] Recent Transactions - On November 3, 2025, CEO Roger E. Susi sold 5,000 shares in an open-market transaction valued at approximately $413,216, based on a weighted average purchase price of $82.64 per share [2][8] - Following the sale, Susi retains an indirect holding of over 2.2 million shares, which represents about 1% of his total equity stake [8] Financial Performance - The company reported a 16% year-over-year increase in third-quarter sales, reaching $21.2 million [11] - Adjusted earnings per share rose by 9% year-over-year to $0.47, indicating strong demand for its MRI-compatible medical devices [11] - Management has raised its full-year sales outlook to $83 million, implying a 13.4% increase for 2025 [11] Stock Performance - Shares of Iradimed increased by approximately 49% during the 12-month period ending November 7, 2025, largely driven by the record third-quarter revenue reported on November 3, 2025 [10]